01884nas a2200337 4500000000100000008004100001653001200042653001500054653002700069653003900096653003300135653001100168653001100179653002400190653000900214653002100223653001800244653002400262100001500286700001500301700001200316700001000328700001200338700001400350700001300364245012500377300001000502490000700512520101300519022001401532 2011 d10aAnimals10aAntibodies10aChorionic Gonadotropin10aClinical Trials, Phase II as Topic10aContraceptive Agents, Female10aFemale10aHumans10aImmunologic Factors10aMice10aMice, Inbred C3H10aMycobacterium10aVaccines, Synthetic1 aPurswani S1 aTalwar G P1 aVohra R1 aPal R1 aPanda A1 aLohiya NK1 aGupta JC00aMycobacterium indicus pranii is a potent immunomodulator for a recombinant vaccine against human chorionic gonadotropin. a24-300 v913 a
The objective of this work was to identify a human use-permissible adjuvant to enhance significantly the antibody response to a recombinant anti-hCG vaccine. Previous Phase II efficacy trials in sexually active women have demonstrated the prevention of pregnancy at hCG bioneutralization titers of 50ng/ml or more. Mycobacterium indicus pranii (MIP), a non-pathogenic Mycobacterium employed as an autoclaved suspension in aqueous buffer, significantly increased antibody titers in the FVB strain of mice. Three other genetic strains of mice: SJL, C3H, and C57Bl/6 responded with antibody titers several-fold higher than 50 ng/ml, which is the protective threshold in women, although there were differences in the peak titers attained. In addition, the duration of the antibody response was lengthened. The vaccine hCGβ-LTB, given together with MIP, induces both a Th1 and Th2 response, which is reflected in the production of not only IgG1, but also a high proportion of IgG2a and IgG2b antibodies.
a1872-7603